Diagnostic procedures using direct injection of gaseous hyperpolarized 129Xe and associated systems and products

• US 6,630,126 B2
• Filed: 03/12/2001
• Issued: 10/07/2003
• Est. Priority Date: 03/13/2000
• Status: Expired due to Fees

• Current Assignee: Polarean, Inc. (Polarean Imaging Plc)
• Original Assignee: Medi-Physics Incorporated (General Electric Company), University of Virginia Patent Foundation (University of Virginia)
• Inventors: Hagspiel, Klaus D., Fujii, Dennis, Driehuys, Bastiaan, Brookeman, James R.
• Primary Examiner(s): Hartley, Michael G.
• Application Number:
  US09/804,369
• Publication Number:
  US 20020006382A1
• Time in Patent Office: 939 Days
• Field of Search: 424/9.3, 436/173, 600/410, 600/420, 534/7
• US Class Current: 424/9.3
• CPC Class Codes: A61B 5/055 involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• CPC Class Codes: A61B 5/416 the spleen
• CPC Class Codes: A61K 49/1815 compo-inhalant, e.g. breath tests
• CPC Class Codes: A61M 5/1483 using flexible bags externally pressurised by fluid pressure
• CPC Class Codes: G01R 33/5601 involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

Abstract

A method of screening for pulmonary embolism uses gaseous phase polarized ¹²⁹Xe which is injected directly into the vasculature of a subject. The gaseous ¹²⁹Xe can be delivered in a controlled manner such that the gas substantially dissolves into the vasculature proximate to the injection site. Alternatively, the gas can be injected such that it remains as a gas in the bloodstream for a period of time (such as about 8-29 seconds). The injectable formulation of polarized ¹²⁹Xe gas is presented in small quantities of (preferably isotopically enriched) hyperpolarized ¹²⁹Xe and can provide high-quality vasculature MRI images or NMR spectroscopic signals with clinically useful signal resolution or intensity. One method injects the polarized ¹²⁹Xe as a gas into a vein and also directs another quantity of polarized gas into the subject via inhalation. In this embodiment, the perfusion uptake allows arterial signal information and the injection (venous side) allows venous signal information. The dual delivery is used to generate a combined introduction path with a more complete image signal of both the arterial and venous side of the pulmonary vasculature. In this NMR imaging method, the pulmonary embolism screening method can use the same NMR chest coil for the excitation and detection of the ¹²⁹Xe signals. The direct injection of small quantities of gas at particular sites along the vasculature targets specific target regions to provide increased signal intensity NMR images. The disclosure also includes related methods directed to other diagnostic vasculature regions physiological and conditions. Associated delivery and dispensing systems and methods, containers, and quantitative formulations of the polarized gas are also described.

Claims

1. A method of evaluating a subject, comprising the steps of:

positioning a subject having a pulmonary region and a blood circulation path including veins and arteries in an NMR system, the subject'"'"'s pulmonary region having pulmonary veins and pulmonary arteries and associated vasculature defining a pulmonary portion of the circulation path;

injecting a first quantity of polarized gaseous phase ¹²⁹Xe directly into at least one vein of the subject, wherein the first quantity of polarized gaseous phase ¹²⁹Xe is less than about 100 cubic centimeters;

obtaining NMR signal data associated with the injected polarized ¹²⁹Xe in the pulmonary region of the subject, the signal data including information corresponding to the polarized gas introduced in said injecting step;

generating an MRI image having spatial visual representation of the NMR signal data of the injected polarized ¹²⁹Xe;

identifying the presence of at least one condition of blockage, restriction, abnormality, and substantially unobstructed free passage of the pulmonary circulation path;

providing a container configured to hold the first injectable quantity of polarized gaseous ¹²⁹Xe therein;

preparing the container to hold the first injectable quantity of polarized gaseous ¹²⁹Xe therein by introducing then expelling CO₂ from the container thereby leaving residual traces of CO₂ therein; and

then

introducing the first quantity of polarized gaseous ¹²⁹Xe into the container prior to the step of injecting.

2. A method according to claim 1, further comprising the step of controlling the rate of injection to less than about 3 cc/s at which the injecting step is performed to thereby control the delivery rate of the polarized gaseous ¹²⁹Xe into the vein.

3. A method according to claim 1, wherein said injected quantity is less than about 20 cc'"'"'s.

4. A method according to claim 1, wherein said identifying step includes determining based on said injecting into the vein step whether the pulmonary circulatory path is blocked or restricted based on the presence of polarized ¹²⁹Xe in the pulmonary arteries.

5. A method according to claim 1, wherein said obtaining step includes obtaining NMR signal data associated with the presence of gaseous phase polarized ¹²⁹Xe in the lungs, the image signal intensity of which corresponds to the restriction, blockage or free passage of the pulmonary circulatory path.

6. A method according to claim 5, wherein after said injection step, a portion of the injected polarized gaseous polarized ¹²⁹Xe travels along a portion of the pulmonary circulation path and subsequently enters the lung cavity in a quantity sufficient to provide NMR data with an associated signal intensity, a decreased signal intensity corresponding to the presence of a blockage or restriction in the pulmonary circulation path.

7. A method according to claim 1, further comprising the step of administering the injection such that the gaseous polarized ¹²⁹Xe substantially dissolves into the vesculature proximate to the injection site.

8. A method according to claim 2, wherein the controlled injection rate is less than about 2 cc/s.

9. A method according to claim 1, wherein said injecting step is carried out such that a major portion of the gaseous polarized ¹²⁹Xe remains substantially as a gas in the bloodstream and exhibits a T₁ in the bloodstream which is greater than about 8 seconds.

10. A method according to claim 1, wherein said NMR signal data obtaining step is performed in a low magnetic field, wherein the field strength is less than about 0.5T.

11. A method according to claim 10, wherein the signal peaks associated with the ¹²⁹Xe in plasma and the ¹²⁹Xe in red blood cells overlap to increase signal intensity associated therewith.

12. A method according to claim 1, further comprising the step of introducing a second quantity of a polarized gas to a subject via inhalation during a single imaging session.

13. A method according to claim 1, wherein said injection step is carried out intravenously.

14. A method according to claim 13, wherein said injection step is carried out via a hypodermic syringe, and wherein said syringe includes gas contacting surfaces which are formed from polarization friendly materials.

15. A method according to claim 12, wherein the second polarized gas comprises ¹²⁹Xe.

16. A method according to claim 15, wherein said obtaining step includes the steps of:

exciting and receiving signal data associated with both the first and second quantities of ¹²⁹Xe with a single transmit/receive excitation coil; and

analyzing the NMR signal data associated with said exciting and receiving step in a way which distinguishes gaseous phase ¹²⁹Xe from the dissolved ¹²⁹Xe in said image generation step.

17. A method according to claim 1, wherein said injection comprises multiple sequential injections thereby allowing for multi-shot MR imaging.

18. A method according to claim 14, wherein the first quantity of polarized ¹²⁹Xe is isotopically enriched.

19. A method according to claim 1, wherein the first quantity of injectable polarized gaseous ¹²⁹Xe is formulated for in vivo human administration.

20. A method according to claim 1, wherein the first quantity of injectable polarized gaseous ¹²⁹Xe is In a quantity less than about 5 cubic centimeters.

21. A method according to claim 1, further comprising evaluating the effectiveness of a therapeutic treatment based on the identifying step.

22. A method according to claim 1, wherein the preparing step is carried out by pressurizing the container wit a quantity of CO₂ and then evacuating the container to remove the CO₂ therefrom.

23. A method according to claim 22, further comprising repeating the pressurizing and evacuating steps a plurality of times to reduce the amount of oxygen in the container prior to the step of introducing the gaseous polarized ¹²⁹Xe therein.

24. A method according to claim 12, further comprising obtaining an MRI ventilation image based on the inhaled polarized gas.

25. A method according to claim 24, wherein the generating step comprises generating a perfusion image based on the activity of the polarized 129Xe after the injecting step, and further comprising combining the ventilation image with the perfusion image to generate a combination image.

27. A method according to claim 24, further comprising calculating the value of the ratio of the volume versus flow rate of the circulatory system of the subject.

28. A method according to claim 2, wherein the controlled injection rate is between about 1-5 cc/s.

29. A method according to claim 1, wherein the obtaining step is commenced within about 5-25 seconds after the initiation of the injecting step.

30. A method according to claim 29, wherein the obtaining step is completed within about 60 seconds after the injecting step.

26. A method the inhaled polarized gas comprises gaseous ¹²⁹Xe in a second quantity that is larger than the injected quantity.

31. A method for evaluating a subject, comprising the steps of:

positioning a subject having a pulmonary region and a blood circulation path including veins and arteries in an NMR system, the subject'"'"'s pulmonary region having pulmonary veins and pulmonary arteries and associated vasculature defining a pulmonary portion of the circulation path;

injecting a first quantity of polarized gaseous phase ¹²⁹Xe directly into at least one vein of the subject, wherein the first quantity of polarized gaseous phase ¹²⁹Xe is less than about 100 cubic centimeters;

obtaining NMR signal data associated with the injected polarized ¹²⁹Xe in the pulmonary region of the subject, the signal data including information corresponding to the polarized gas introduced in said injecting step;

generating an MRI image having spatial visual representation of the NMR signal data of the injected polarized ¹²⁹Xe;

identifying the presence of at least one condition of blockage, restriction, abnormality, and substantially unobstructed free passage of the pulmonary circulation path; and

introducing a quantity of surfactant into a subject proximate to the injection site of the ¹²⁹Xe.

32. A method according to claim 31, wherein the surfactant introduction is carried out so that the surfactant and ¹²⁹Xe are injected separately into the subject.

33. A method according to claim 31, wherein the subject is a human subject, and wherein the surfactant is injected in vivo to a human subject after the polarized gaseous ¹²⁹Xe is injected.